Top

Drugs

Published in:

Open Access 01-06-2018 | Letter to the Editor

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Authors: Hillel P. Cohen, Andrew Blauvelt, Robert M. Rifkin, Silvio Danese, Sameer B. Gokhale, Gillian Woollett

Published in: Drugs | Issue 8/2018

Excerpt

Dear Editor, …

Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78:463–78.CrossRefPubMedPubMedCentral

Pires A, Goyal K, Greenspan A. Comment on: “Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes”. Drugs. 2018. https://doi.org/10.1007/s40265-018-0918-2.PubMedCrossRefPubMedCentral

Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jon AJL, van der Lann WH, van der Hoogen FHJ, et al. Clinical and immunogenicity outcomes after switching treatment from innovator infliximab to biosimilar infliximab in rheumatic diseases in daily clinical practice. Arthritis Rheumatol. 2016;68(suppl 10):820–2.

Tweehuysen L, Bart J, van den Bemt BJF, van Ingen IL, de Jon AJL, van der Lann WH, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70:60–8.CrossRefPubMed

Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–31.CrossRefPubMed

Avouac J, Molto A, Abitbol V, Etcheto A, Salcion A, Gutermann L, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory rheumatic diseases in daily clinical practice: the experience of Cochin Hospital, Paris, France. Ann Rheum Dis. 2017;76(suppl 2):831.

Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, et al. The PROSIT-1 BIO Cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23(2):233–43.CrossRefPubMed

Yazici Y, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, et al. A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab. Arthritis Rheumatol. 2016;68(Supp 10):2902–5.

Phillips K, Juday T, Zhang Q, Keshishian A. Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or CT-P13 in the Turkish population. Ann Rheum Dis. 2017;76(suppl 2):835.

10.

Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509–19.CrossRefPubMed

11.

Holroyd C, Wallis D, Bennett S, Clayton P, Edwards CJ. Switching from bio-original etanercept to biosimilar etanercept SB4: patient acceptability and outcomes in the real world. EULAR 2017; Abstract AB0377. Accessed 23 Apr 2018.

12.

Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohn’s Colitis. 2017;11:690–6.

13.

US Dept HHS, Food and Drug Administration. Guidance for industry: draft guidance: considerations in demonstrating interchangeability with a reference product. 2017. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed 11 Apr 2018.

14.

International Conference on Harmonisation; Guidance on Q5E. Comparability of biotechnological/biological products subject to changes in their manufacturing process. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. Accessed 11 Apr 2018.

15.

Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–8.CrossRefPubMed

16.

Balázs V, Zsuzsanna B, Miklós S, Zsombor Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016;32:829–34.CrossRef

17.

Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H-J, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–2.CrossRefPubMed

18.

Kim S, Song J, Park S, Ham S, Paek K, Kang M, et al. Drifts in ADCC-related quality attributes of Herceptin^®: impact on development of a trastuzumab biosimilar. mAbs. 2017;9:704–14.CrossRefPubMedPubMedCentral

Title: Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
Authors: Hillel P. Cohen
Andrew Blauvelt
Robert M. Rifkin
Silvio Danese
Sameer B. Gokhale
Gillian Woollett
Publication date: 01-06-2018
Publisher: Springer International Publishing
Published in: Drugs / Issue 8/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-018-0919-1

2024 ASCO Annual Meeting

Springer Medicine

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2018

Management of Embolic Stroke of Undetermined Source (ESUS)

Tildrakizumab: First Global Approval

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Colorectal Cancer: Why Does Side Matter?

Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?

Correction to: Ibalizumab: First Global Approval